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Abstract
Background: The Dutch Working Party on Antibiotic Policy is developing a national antimicrobial stewardship
registry. This registry will report both the quality of antibiotic use in hospitals in the Netherlands and the
stewardship activities employed. It is currently unclear which aspects of the quality of antibiotic use are monitored
by antimicrobial stewardship teams (A-teams) and can be used as indicators for the stewardship registry. In this
pilot study we aimed to determine which stewardship objectives are eligible for the envisioned registry.
Methods: We performed an observational pilot study among five Dutch hospitals. We assessed which of the 14
validated stewardship objectives (11 process of care recommendations and 3 structure of care recommendations)
the A-teams monitored and documented in individual patients. They provided, where possible, data to compute
quality indicator (QI) performance scores in line with recently developed QIs to measure appropriate antibiotic use
in hospitalized adults for the period of January 2015 through December 2015
Results: All hospitals had a local antibiotic guideline describing recommended antimicrobial use. All A-teams
monitored the performance of bedside consultations in Staphylococcus aureus bacteremia and the prescription of
restricted antimicrobials. Documentation and reporting were the best for the use of restricted antimicrobials: 80% of
the A-teams could report data. Lack of time and the absence of an electronic medical record system enabling
documentation during the daily work flow were the main barriers hindering documentation and reporting.
Conclusions: Five out of 11 stewardship objectives were actively monitored by A-teams. Without extra effort, 4 A-teams
could report on the quality of use of restricted antibiotics. Therefore, this aspect of antibiotic use should be the starting
point of the national antimicrobial stewardship registry. Our registry is expected to become a powerful tool to evaluate
progress and impact of antimicrobial stewardship programs in hospitals.
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Background
Inappropriate use of antibiotics contributes to the grow-
ing problem of antimicrobial resistance, which is a ser-
ious threat to public health [1]. Hospital-based programs
dedicated to improve antibiotic use, commonly referred
to as “Antibiotic Stewardship Programs” (ASPs), aim to
optimize the treatment of infections, reduce adverse
events including antibiotic resistance, and to improve
patient outcome [2]. To curb antimicrobial resistance,
the Dutch Health Care Inspectorate and the Minister of
Health have recommended the establishment of anti-
microbial stewardship teams (A-teams) in every hospital.
Since 2014, most Dutch hospitals have started the imple-
mentation of ASPs by A-teams.
To measure the progress and impact of the national
implementation of antimicrobial stewardship, the Dutch
Working Party on Antibiotic Policy (SWAB) aims to de-
velop an antimicrobial stewardship registry. A registry is
an organized system that uses observational study
methods to collect uniform data to evaluate specified
outcomes for a defined population and that serves one
or more predetermined scientific, clinical, or policy pur-
poses [3]. Quality focused registries -assessing quality of
care and quality improvement- are increasingly created
to measure differences in quality of care between pro-
viders or patient populations. These registries collect
data in the form of process of care indicators [3].
Process indicators assess healthcare service delivered to
patients by healthcare providers [4]. These data may be used
to, for example, demonstrate opportunities for improve-
ment, or provide transparency through public reporting.
The national antimicrobial stewardship registry will re-
port on an annual basis both the quality of antibiotic use
in hospitals in the Netherlands and the stewardship ac-
tivities employed by the A-teams. In this manner, the es-
tablishment of a comprehensive and detailed prospective
quality-focused registry continuously provides data on
the progress and impact of implementation of ASPs in
Dutch hospitals. These data will be published in Neth-
map, the annual national report which currently reports
on consumption of antimicrobial agents and on anti-
microbial resistance patterns [5].
The value of clinical registries have been shown to
improve quality of care in studies in patients with se-
vere infections admitted to the hospital [6, 7], but
also in patients treated in an ambulatory setting with
antibiotics [8]. To our knowledge, our registry will be
the first national, quality focused, registry for hospital
antimicrobial use.
It is currently unclear which quality of antibiotic use
aspects are monitored in daily practice by A-teams and
can be used as indicators for the stewardship registry.
The selection of these indicators requires balancing the
goals of the registry with the desire to meet the needs of
the providers. For example: data should be readily avail-
able for measurement and retrievable without undue
burden, and providing useable and relevant information
[3]. Ideally, these indicators are already integrated in the
daily workflow of the providers. Therefore, we per-
formed a pilot study to assess the availability of data on
quality of antibiotic use currently monitored and docu-
mented by Dutch A-teams, which could be a starting
point for the national registry.
Methods
Setting & study population
An observational pilot study was performed in 2 univer-
sity and 3 non-university hospitals (one small hospital
and two large teaching hospitals). These 5 hospitals were
selected since they had operational, experienced A-
teams. They were thought to be able to demonstrate the
variety of ‘what can be monitored, documented and re-
ported’ during daily practice in a non-study setting.
Hospital and A-team characteristics
The composition and year of establishment of the A-
teams, number of hospital beds, and the presence of an
Electronic Medical Record System and/or Electronic
Prescribing System were recorded.
Monitoring, documenting and reporting recommended
antimicrobial use: Stewardship objectives and QIs
We visited each hospital for a systematic assessment.
The A-teams were scored on 14 predefined stewardship
objectives (Table 1). Eleven of these objectives reflect
processes of care at the individual patient level. We
asked A-team members whether they monitored patients
in line with each objective and whether they docu-
mented the appropriateness of antibiotic use in those pa-
tients (Table 2).
To assess their ability to report hospital specific data
on the quality of antibiotic use, we explored what data
were readily available to compute process indicator per-
formance scores. Such scores can be described as a per-
centage between 0 and 100 where the numerator
represents the number of patients in whom antibiotics
are used as defined, and the denominator represents the
eligible target population. Next, we collected these data
to compute QI performance scores in line with the re-
cently developed quality indicators to measure appropri-
ate antibiotic use in hospitalized adults for the period of
January 2015 through December 2015 [9].
Similarly, information on the 3 stewardship objectives
reflecting organization of care was collected by asking
whether the recommendations on the organization of
care -as defined using the structure QIs- were met or
not in each hospital. Additional local initiatives aimed at
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measuring the quality of antibiotic use were also taken
into account.
All available data were collected and extracted in a uni-
form way. If an A-team was not able to provide data,
barriers to registration were discussed during the site visit
with a member of the A-team. QI performance scores were
computed for all indicators that could be reported by two
or more hospitals (Table 1). The comparison of the results
Table 1 Stewardship objectives reflecting processes and organization of care, and the corresponding quality indicators
Number Stewardship objective, process of care
recommendation
Corresponding quality indicator
Numerator description Denominator description
1 Take 2 sets of blood cultures before
starting antibiotic therapy
Number of patients in whom at least 2 sets of
blood cultures were taken before systemic
antibiotic therapy was started
Total number of patients who started with
empirical systemic antibiotic therapy
2 Take cultures from suspected sites of
infection
Number of patients in whom cultures from
suspected sites of infections were taken within
24 h after the systemic antibiotics were started
Total number of patients who started with
systemic antibiotic therapy
3 Prescribe
empirical antibiotic therapy according
to local guidelinea
Number of patients who started with empirical
systemic antibiotic therapy according to the
national guideline
Total number of patients who started with
empirical systemic antibiotic therapy
4 Adapt antibiotic dosage to renal
function
Number of patients with a compromised renal
function with a dosing regimen adjusted to
renal function
Total number of patients who started with
systemic antibiotic therapy which should be
dosed according to renal function, and who
had an unknown or compromised renal
function.
5 Document antibiotic plan Number of patients for whom an antibiotic plan
was documented in the case notes
Total number of patients who started with
systemic antibiotic therapy
6 Change empirical to pathogen-directed
therapy
Number of patients with empirical therapy
whose culture became positive and changing
to pathogen-directed therapy was done
correctly.
Total number of patients with empirical
systemic antibiotics, whose culture became
positive
7 Switch from intravenous to oral
therapy on the basis of the clinical
condition and when oral treatment is
adequate
Number of patients with intravenous antibiotics
for 48-72 h, in whom changing to oral antibiotic
therapy on the basis of clinical conditions was
done.
Total number of patients with intravenous
antibiotics for 48-72 h, in whom changing to
oral antibiotic therapy on the basis of the clin-
ical condition was indicated
8 Perform therapeutic drug monitoring
when the therapy is >3 days for
aminoglycosides and >5 days for
vancomycin
Number of patients on aminoglycosides or
vancomycine in whom a serum drug level has
been determined after respectively >3 or
>5 days of therapy
Total number of patients who received
aminoglycosides for >3 days and/or
vancomycin for >5 days
9 Discontinue antibiotic therapy if
infection is not confirmed
Number of patients whose empirical antibiotic
therapy was discontinued within 7 days based
on the lack of clinical and/or microbiological
evidence of infection.
Total number of patients who started empirical
systemic antibiotic therapy, but lacked clinical
and/or microbiological evidence of infection.
10 Perform ID specialist bedside
consultations in hospitalized patients
with a Staphylococcus aureus
bacteremia
Number of patients with Staphylococcus aureus
bacteremia who had a bedside consultation of
an ID specialist
Total number of patient with a Staphylococcus
aureus bacteremia
11 Assess patients’ adherence Number of patients adherent to the
prescription’s instructions
Total number of patients with a prescription of
antibiotics
Stewardship objective, organization of
care recommendation
12 A local antibiotic guideline should be
present and an update should be done
every 3 years
13 The local guidelines should correspond
to the national antibiotic guidelines but
deviate based on local resistance
patterns
14 A list of restricted antibiotics should be
present
aantibiotics on a list of “restricted” and “limited prescription” antimicrobial drugs
The numerator and denominator described in the third and fourth column were used to calculate quality indicator performance. [9]
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between the hospitals was not the primary aim of this
study. Instead, we focused on assessing the possibility to
provide data about the quality of antibiotic use. For this
study, no approval of a medical ethics committee was re-
quired, since it was part of quality control of drug
utilization, observational in nature, data used for this study
were already available in the electronic patient records, and
data were provided and processed anonymously.
Results
Hospital and A-team characteristics
We included 5 hospitals: 2 academic teaching hospitals
with approximately 1000 beds, 2 smaller teaching hospitals
with approximately 500 beds, and 1 hospital with approxi-
mately 250 beds. The characteristics of the 5 A-teams are
shown in Table 3. The 5 A-teams included in this study
operated on a daily basis, except for the weekends.
Monitoring and documentation
Regarding the organization of care objectives, all 5 hos-
pitals had a local antibiotic guideline that corresponded
to the national guideline and had been updated at least
every 3 years. All 5 hospitals had a list of antibiotics that
were restricted or had limited indication according to
the list published in The Antimicrobial Stewardship
Practice Guide for the Netherlands [10]. Restricted anti-
biotics (such as carbapenems and glycopeptides) have
been defined as drugs that only should be prescribed for
microorganisms that are resistant to the usual drugs.
Limited indication antibiotics are drugs that are indi-
cated for some indications but should not be used in
other situations (such as quinolones and third gener-
ation cephaloporins).
Only 2 hospitals used an electronic medical record sys-
tem for documenting process of care objectives, which en-
abled automatic data extraction. The other hospitals had
written patient files in combination with an electronic pre-
scribing system. In those hospitals, a member of the A-
team manually recorded data in a spreadsheet.
Of the 11 process of care objectives, 5 were monitored
by at least one of the A-teams during the study period
(Table 4). Only 2 objectives were monitored by all A-
teams: [1] prescribe restricted antibiotics and limited
prescription antibiotics according to local guideline, and
[2] perform bedside consultations for S. aureus
bacteremia (Table 4).
In all hospitals, a daily list of patients on restricted an-
tibiotics or limited prescription antibiotics was gener-
ated, either automatically in the Electronic Medical
Record, or manually by the pharmacy department. The
prescriptions were evaluated for appropriateness (i.e. in
accordance with the local guideline) by a local A-team
member and an advice to the prescriber was given when
necessary. One of these 4 hospitals monitored restricted
antibiotics during a four-month period, the others per-
formed continuous monitoring in 2015 (prospective
audit and feedback). One A-team reviewed all prescribed
antibiotics for appropriateness instead of only restricted
and limited prescription antibiotics.
Four out of 5 hospitals documented the appropriate-
ness of the use of restricted antibiotics and limited
Table 2 Example of monitoring, documentation and reporting
of a stewardship objective
Monitoring: a local member of the A-team assesses empirically pre-
scribed restricted antibiotics for accordance with the local guideline,
using daily generated lists (Stewardship objective 3, Table 1).
Documentation: The A-team member documents both the appropriate
and inappropriate prescriptions, including the prescribing department.
Reporting: Each department receives an annual report about the quality
of empirical use of restricted antibiotics. Quality indicator performance is
presented as the percentage of appropriate prescriptions.
Table 3 Characteristics of the participating hospitals and their A-teams
Hospital A B C D E
Number of hospital beds 1002 953 268 554 543
A-team composition Hospital pharmacist + + + + +
ID specialist + + + + +
Microbiologist + + + + +
Information technician − − − − +
Nurse − − + − −
Quality of care specialist − + − − −
Year of establishment of A-team 2014 2015 2013 2014 2014
Total numbers of prescriptions documented 343 1824 1729 575 436
Electronic Medical Record Present − + − − +a
Electronic Prescribing System Present + + + + +
Abbreviations: ID infectious disease
aonly partially: written patient record but laboratory and microbiology results are accessible via Electronic Medical Record
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prescription antibiotics. The appropriateness (appropri-
ate, inappropriate, indeterminate) of the prescriptions
was recorded either in the patient chart or in a
spreadsheet.
Four hospitals monitored therapeutic drug monitoring
(TDM) in patients treated with aminoglycosides or
vancomycin. Only one hospital documented data about
the numbers of patients with an indication for TDM and
whether drug levels were determined in this population.
An iv-oral switch monitoring program was performed
in 3 of 5 hospitals: after 48–72 h on intravenous (iv)
antibiotic therapy a local member of the A-team deter-
mined whether a patient was eligible for iv to oral
switch, based on predefined switch criteria [11]. Appro-
priateness was documented by 2 A-teams only (Table 4).
During a three-month period in 2015, hospital B docu-
mented which patients could be safely switched to an
oral formulation 48-72 h after initiation, but did not pro-
vide advice to the prescribing physician. A second chart
review was done 2 days after the initial assessment in
hospital B to determine which patients were switched
without an intervention of the A-team. The purpose of
that local pilot study was to determine the need for
monitoring incorrect iv-oral switch at specific wards.
This showed that a switch was possible in 35% of all pa-
tients treated intravenously, but that this was only per-
formed in 47% of the eligible cases. Metronidazole and
amoxicillin were the antibiotics most often incorrectly
continued intravenously.
Hospital C documented the cases for which a switch
was recommended and performed, but the denominator
(the total number of patients eligible for switch) was not
documented, making it impossible to determine the
quality indicator performance in that hospital.
One A-team monitored and documented on a daily
basis all culture results and other microbiological proce-
dures performed in patients empirically treated with
antibiotics.
All hospitals monitored bedside consultation by an ID
specialist in patients with S. aureus bacteremia. Data re-
garding the adherence to this objective was available in
one hospital.
The 2 most frequently mentioned barriers for the lack
of documentation were lack of time and the absence of
an electronic medical record system enabling the docu-
mentation during the daily work flow.
Reporting
A total number of 4907 (range 343–1824) prescriptions
were monitored and documented by the local A-teams
in 2015. To compute QI performance scores in line with
quality indicators to measure appropriate antibiotic use
in hospitalized adults, both the numerator and the de-
nominator had to be known. One A-team documented
Table 4 Monitoring, documenting and reporting the quality of antibiotic use by A-teams
Hospital
Process of care recommendation Activity A B C D E Total
Blood cultures taken? Monitored − − − + − 1/5 (20%)
Documented − − − + − 1/5 (20%)
Reported − − − + − 1/5 (20%)
Antibiotics prescribed according to local guideline? Monitored + + + + + 5/5 (100%)
Documented + + + + + 4/5 (80%)
Reported + + + + -* 1/5 (20%)
Therapy switched from intravenous to oral therapy? Monitored − + + − + 3/5 (60%)
Documented − + + − − 2/5 (40%)
Reported − + -* − − 1/5 (20%)
Therapeutic drug monitoring performed? Monitored − + + + + 4/5 (80%)
Documented − + − − − 1/5 (20%)
Reported − + − − − 1/5 (20%)
Bedside consultation performed for S.aureus bacteremia? Monitored + + + + + 5/5 (100%)
Documented − + − − − 1/5 (20%)
Reported − + − − − 1/5 (20%)
Organization of care recommendation
Local antibiotic guideline is present + + + + + 5/5 (100%)
Local guideline corresponds to national guideline + + + + + 5/5 (100%)
List of restricted antibiotics is present + + + + + 5/5 (100%)
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the numbers of guideline-adherent prescriptions only,
but could not report the denominator (the total number
of antibiotic prescriptions). Unfamiliarity with the pur-
pose of process indicators (problem identification, evalu-
ation of interventions, and benchmarking) was the main
reason for this missing information.
Comparing QI performance scores was possible for
the appropriateness of glycopeptide, fluoroquinolone
and carbapenem prescriptions for 4 hospitals (Fig. 1).
Pre-authorisation by the medical microbiologist for gly-
copeptide prescriptions was mandatory in one hospital,
which resulted in 100% appropriateness as judged by the
A-team. Regarding the fluoroquinolones, 1 hospital (hos-
pital D, Figure 1) only monitored the use of levofloxacin.
Discussion
This observational pilot study investigated which steward-
ship objectives were monitored, documented and could be
reported for the purpose of establishing a national anti-
microbial stewardship registry. Our results showed that all
A-teams have an antibiotic guideline available, and that
monitoring is performed for only part of the recommended
stewardship objectives. Furthermore, most A-teams have
already implemented data collection and documentation
for some of the appropriate antibiotic use aspects, enabling
the measurement of QIs.
The initiative of the SWAB to establish an antimicro-
bial stewardship registry enables the measurement of the
progress and impact of the national implementation of
antimicrobial stewardship, and provides feedback to hos-
pitals, which can be used to improve quality of antibiotic
use in daily practice. This monitor should, ultimately, at
least include the 14 stewardship objectives. From a view-
point of data availability and feasibility, our results sug-
gest that the antimicrobial stewardship registry should,
firstly, focus on the appropriateness of the use of re-
stricted antibiotics and limited prescription antibiotics.
Additional QIs can be subsequently introduced into the
monitor. It is important that new QIs should always be
in line with the possibilities of the A-teams to provide
data. Other aspects that should be taken into account
when extending the monitor are the clinimetric proper-
ties of the QIs: measurability, applicability, inter-
observer reliability, room for improvement and case mix
stability. A recent observational multicenter study in-
cluding 1890 patients receiving antibiotics for a sus-
pected bacterial infection in 22 hospitals in the
Netherlands concluded that seven of the QIs (which
were also used in the present study) had sound clini-
metric properties, whereas low applicability (i.e. QI ap-
plies to ≤10% of the reviewed patients) was found for
the QIs ‘therapeutic drug monitoring’, ‘adapting antibi-
otics to renal function’ and ‘discontinue empirical ther-
apy in case of lack of evidence of infection’ [12].
The optimal frequency of measuring quality of care is
not known. Measurements can be performed daily, such
as continuous prospective audit and feedback as per-
formed in the present study, or during a certain time
period (an audit), or by (repeated) point prevalence stud-
ies. Continuous measurements have the advantage that
the quality of care for less common infections and infre-
quently used antibiotics can be measured, that trends
can be easily visualized, and that results are less influ-
enced by season, outbreaks or incidental errors. The big-
gest drawback, however, is its time-consuming nature.
Buyle et al. collected data over a three-month period to
assess the feasibility of a QI for intravenous to oral
switch [13]. The indicator was measurable in 99.1% of
cases, but the median time needed for case assessment
and documentation was 29 min, which is not feasible in
Fig. 1 Appropriateness of antibiotic prescriptions. Number in the bars represents the numbers of prescriptions reviewed per category. In hospital
“D” pre-authorisation for the use of glycopeptides resulted in an appropriateness of 100%
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daily practice. A practical approach could be to replace
continuous measurements with intermittent measure-
ments if the QI performance score is sufficient.
Although systematic documentation of quality of anti-
biotic use was performed to some extent, it was not the
main priority for A-teams. This is in line with previous hos-
pital studies [14, 15]. We believe that standardized docu-
mentation of quality of antibiotic use is a prerequisite for
the assessment of the quality of antibiotic use, providing
valuable information: about the aspects of care that are
most in need of improvement, the progress of implementa-
tion of an ASP and the effect of stewardship activities. The
present study showed that only 10% of glycopeptide pre-
scriptions were inappropriate, while inappropriate use of
fluoroquinolones was common. This implies that identify-
ing determinants for the misuse of fluoroquinolones and
improving the quality of its prescription may be prioritized
over monitoring other areas, such as glycopeptide use. Fur-
thermore, the hospital performance may be used as a
benchmark to gain insight into the national progress of im-
plementation of ASPs and enables the exchange of best
practices between hospitals.
Lack of time and the absence of a systematic and ro-
bust registration system were important barriers for doc-
umenting and therefore reporting the quality of
antibiotic use. In three out of five hospitals, data were
entered manually into a spreadsheet, which is prone to
errors and leads to duplication of work. Nevertheless, al-
though registration systems differed, we showed that 4
out of 5 hospitals could provide reliable data for bench-
mark and quality assessment.
The importance of integrating documentation into the
daily work flow was supported by a recent study identify-
ing barriers for the implementation of an antibiotic check-
list [16]. Therefore, we strongly suggest that every A-team
involves an information technician for data collection and
management, and that hospital boards should support the
introduction of an electronic medical record suitable for
this purpose. To achieve these goals and to implement a
functional ASP, appropriate financial support is needed, as
shown by a recent French study [17]. A study of ASP costs
is currently being performed in the Netherlands to help
the A-teams allocate the resources for the implementation
of ASPs, including the monitoring, documenting and
reporting of the quality of antibiotic use.
Although only 5 hospitals were included in this pilot
study, these varied from small non-university hospitals to
large tertiary centres and can be regarded as representa-
tive of the Dutch hospital care setting. Besides investments
in both human resources and ICT, all A-teams should be
taught the value of documenting and reporting the quality
of antibiotic use. Another important aspect that should be
addressed is the use of uniform formats of data collection
and the completeness of the local guidelines.
Conclusion
Since 2014, the Dutch government requires all hospitals
to establish an A-team. This observational study reports
which aspects of quality of antibiotic use are monitored
and documented by A-teams. At present, the quality of
use of restricted and limited prescription antibiotics is
the best documented ASP activity. In addition, this study
has identified the need to standardize data collection as
the basis for measuring and improving the quality of
antibiotic use in hospitals and as input for the envi-
sioned national antimicrobial stewardship registry.
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